MicroRNA-29b upregulation improves myocardial fibrosis and cardiac function in myocardial infarction rats through targeting SH2B3.

MicroRNA-29b upregulation improves myocardial fibrosis and cardiac function in myocardial infarction rats through targeting SH2B3. Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):10115-10122 Authors: Wang Y, Jin BJ, Chen Q, Yan BJ, Liu ZL Abstract OBJECTIVE: Myocardial fibrosis (MF) seriously affects normal cardiac function. Meanwhile, MF at post-myocardial infarction (MI) is the leading cause of cardiac dysfunction in patients with acute myocardial infarction (AMI). Therefore, the aim of this study was to investigate the potential effect of microRNA-29b on MF and cardiac function after MI in rats. MATERIALS AND METHODS: In vivo MI model was constructed by ligation of the left anterior descending coronary artery in Sprague-Dawley rats. Lentivirus overexpressing microRNA-29b was established and transfected to up-regulate microRNA-29b expression in rat myocardial tissues. The effect of microRNA-29b on luciferase activity of SH2B3 3'UTR was detected by the luciferase reporter gene assay. The mRNA levels of microRNA-29b, SH1B3, COL1A1, and α-SMA in the infarct border zone and cardiomyocytes were detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Meanwhile, the protein levels of SH1B3, COL1A1, and α-SMA in the MI border zone and cardiomyocytes were determined by Western blot. In addition, cardiac function and MF in MI rats were evaluated by echocardiography, hematoxylin and eosin (HE) and Masson staining, respectively. RESUL...
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Related Links:

Publication date: Available online 20 January 2020Source: Artificial Intelligence in MedicineAuthor(s): Oh Shu Lih, V Jahmunah, Tan Ru San, Edward J Ciaccio, Toshitaka Yamakawa, Masayuki Tanabe, Makiko Kobayashi, Oliver Faust, U Rajendra AcharyaAbstractCardiovascular disease (CVD) is the leading cause of death worldwide, and coronary artery disease (CAD) is a major contributor. Early-stage CAD can progress if undiagnosed and left untreated, leading to myocardial infarction (MI) that may induce irreversible heart muscle damage, resulting in heart chamber remodeling and eventual congestive heart failure (CHF). Electrocardiog...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
CONCLUSIONS: Losartan promotes myocardial apoptosis after AMI in the rats through inhibiting the Ang II-induced JAK/STAT pathway. PMID: 31957855 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: CircRNA 010567 siRNA can improve the cardiac function, alleviate the MF, and inhibit the myocardial apoptosis, thereby further suppressing MI-induced MF, whose mechanism may be related to the inhibition on the TGF-β1 signaling pathway. PMID: 31957851 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
New research says heart attack survivors who carry extra weight around their belly are at greater risk of another heart attack.
Source: CNN.com - Health - Category: Consumer Health News Source Type: news
This study constructed the regulatory metabolic network map of Met, elucidated the endogenous metabolic pathway regulated by Met, and validated the new potential therapeutic targets of Met in MI, which might provide a further reference for the clinical application of Met.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
The field of medical AI is buzzing. More and more companies set the purpose to disrupt healthcare with the help of artificial intelligence. Given how fast these companies come and go, it can prove to be hard to stay up-to-date with the most promising ones. Here, I collected the biggest names currently on the market ranging from start-ups to tech giants to keep an eye on in the future. To further help you keep up with what A.I. brings to medicine, The Medical Futurist team made an easy-to-digest e-book about just that. I highly encourage you to read it and would love to hear about your thoughts! Artificial Intelligence has ...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Artificial Intelligence Healthcare Design AI digital health genetics Innovation Personalized medicine pharma GC1 big data drug development healthcare companies medical imaging Source Type: blogs
The objective of this study was to analyze studies on animals that had exercised prior to myocardial infarction and to examine any benefits through a systematic review and meta-analysis. The databases MEDLINE, Google Scholar, and Cochrane were consulted. We analyzed articles published between January 1978 and November 2018. From a total of 858 articles, 13 manuscripts were selected in this review. When animals exercised before experimental infarction, there was a reduction in mortality, a reduction in infarct size, improvements in cardiac function, and a better molecular balance between genes and proteins that exhibit card...
Source: Clinics - Category: General Medicine Source Type: research
AbstractPurpose of ReviewOur review discusses the management of post percutaneous coronary intervention angina (PPCIA) which negatively impacts 20 –40% of patients and imposes a high burden on the healthcare system.Recent FindingsMechanisms of PPCIA include microvascular dysfunction, distal coronary vasospasm or disease, microembolization, myocardial bridge, coronary artery disease (CAD) progression, and rarely stent thrombosis or in-stent restenosis. Nitrates, beta blockers (BB), calcium channel blockers, and ranolazine are the common medical management options. Only BB showed 1-year mortality benefit following myoc...
Source: Current Cardiology Reports - Category: Cardiology Source Type: research
A new study, led by Yale University, found that every time the number of ultrafine particles in the air increased, the risk of a non-fatal heart attack six hours late rose by 3.27 percent.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
In this study, there was no increased risk of adverse outcomes (including muscle aches, liver dysfunction, new onset of diabetes, cancer, and bleeding strokes), even when LDL was lowered to as low as 20 mg/dL. Although statin medications themselves have been linked to side effects, especially at high doses, it appears that extremely low LDL concentrations are not responsible for side effects. In other words, lowering LDL beyond our previous target of 70 mg/dL appears to be not only safe but beneficial, in patients with CVD. The post LDL cholesterol: How low can you (safely) go? appeared first on Harvard Health Blog.
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Drugs and Supplements Health Heart Health Source Type: blogs
More News: Cardiology | Drugs & Pharmacology | Genetics | Heart | Heart Attack | Study